Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.70 |
| ▸ | HPGD | P15428 | 8/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345129 | 0.85 | FGFR1 (0.70) | FGFR1HPGDALDH1A1LMNAMAPT | |
| SCHEMBL2365060 | 0.85 | HPGD (0.70) | FGFR1HPGDALDH1A1LMNANPSR1 | |
| SCHEMBL2570944 | 0.82 | FGFR1 (1.00) | FGFR1HPGDLMNAMAPTRAB9A | |
| SCHEMBL2340069 | 0.80 | FGFR1 (0.62) | FGFR1HPGDALDH1A1LMNAMAPT | |
| SCHEMBL2340072 | 0.80 | FGFR1 (0.77) | FGFR1HPGDALDH1A1MAPTRAB9A | |
| SCHEMBL2079036 | 0.79 | FGFR1 (0.71) | FGFR1HPGDALDH1A1LMNAMAPT | |
| SCHEMBL30158930 | 0.79 | FGFR1 (0.71) | FGFR1HPGDALDH1A1LMNAMAPT | |
| SCHEMBL9630993 | 0.76 | FGFR1 (0.63) | FGFR1HPGDALDH1A1MAPTRAB9A | |
| SCHEMBL4502855 | 0.76 | FGFR1 (0.79) | FGFR1HPGDALDH1A1MAPTRAB9A | |
| SCHEMBL3490440 | 0.76 | FGFR1 (0.56) | FGFR1HPGDALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831206-B1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARM INC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-7419995-B2 | N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | KIT, CHUK, TNNI3K | FGFR1 1333/4885HPGD 1642/4885ALDH1A1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.